Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery

INTRODUCTION: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been suff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gallmeier, Eike, Bader, Dominik C., Kriegl, Lydia, Berezowska, Sabina, Seeliger, Hendrik, Göke, Burkhard, Kirchner, Thomas, Bruns, Christiane, De Toni, Enrico N.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3584093/
https://ncbi.nlm.nih.gov/pubmed/23460812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0056760
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados